A Phase 2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Descriptive Efficacy of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BRII 296 (Primary)
Indications Postnatal depression
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Brii Biosciences

22 Mar 2024 According to a Brii Biosciences media release, In September 2023, the first patient was dosed in the Phase 2 study evaluating BRII-296, a long-acting injectable (LAI) therapy in development for PPD. Company expects data readouts from the Phase 2 trial by the second quarter of 2024.
21 Mar 2024 Status changed from active, no longer recruiting to completed.
10 Jan 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com